tiprankstipranks
Consun Pharmaceutical Group Ltd. (DE:C1P)
:C1P
Germany Market

Consun Pharmaceutical Group Ltd. (C1P) Financial Statements

Compare
2 Followers

Consun Pharmaceutical Group Ltd. Financial Overview

Consun Pharmaceutical Group Ltd.'s market cap is currently €829.73M. The company's EPS TTM is €0.134; its P/E ratio is 6.52; and it has a dividend yield of 8.11%. Consun Pharmaceutical Group Ltd. is scheduled to report earnings on March 19, 2025, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue¥ 2.59B¥ 2.34B¥ 2.04B¥ 1.75B¥ 1.73B
Gross Profit¥ 1.92B¥ 1.76B¥ 1.53B¥ 1.32B¥ 1.26B
Operating Income¥ 884.97M¥ 715.41M¥ 660.18M¥ 550.13M¥ 496.38M
EBITDA¥ 963.06M¥ 785.89M¥ 728.71M¥ 618.79M¥ 566.36M
Net Income¥ 784.53M¥ 682.91M¥ 590.17M¥ 498.79M¥ 79.82M
Balance Sheet
Cash & Short-Term Investments¥ 3.58B¥ 3.04B¥ 2.43B¥ 1.94B¥ 1.38B
Total Assets¥ 5.51B¥ 4.89B¥ 4.36B¥ 3.95B¥ 3.71B
Total Debt¥ 511.53M¥ 460.18M¥ 610.97M¥ 549.41M¥ 553.57M
Net Debt¥ -2.24B¥ -1.99B¥ -1.59B¥ -1.39B¥ -829.66M
Total Liabilities¥ 1.59B¥ 1.45B¥ 1.45B¥ 1.43B¥ 1.40B
Stockholders' Equity¥ 3.63B¥ 3.15B¥ 2.62B¥ 2.22B¥ 1.99B
Cash Flow
Free Cash Flow¥ 766.41M¥ 896.09M¥ 627.29M¥ 818.36M¥ 203.57M
Operating Cash Flow¥ 818.97M¥ 947.68M¥ 725.54M¥ 867.06M¥ 383.31M
Investing Cash Flow¥ -231.77M¥ -368.80M¥ -298.31M¥ -25.70M¥ -110.13M
Financing Cash Flow¥ -280.10M¥ -342.20M¥ -166.66M¥ -279.80M¥ -156.66M
Currency in CNY

Consun Pharmaceutical Group Ltd. Earnings and Revenue History

Consun Pharmaceutical Group Ltd. Debt to Assets

Consun Pharmaceutical Group Ltd. Cash Flow

Consun Pharmaceutical Group Ltd. Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis